Pharmaceutical manufacturers reported on Friday that supplies of estrogen patches continue to face disruptions in the U.S. due to a sharp increase in patient demand. While several drugmakers have reported shortages at the manufacturing level, the Food and Drug Administration (FDA) has not yet added estradiol patches to its official national shortage list. The agency stated that current supplies remain sufficient to meet national needs as other manufacturers absorb the supply gaps.
The spike in demand follows a November decision by the Department of Health and Human Services (HHS) to lift a "black box" warning—the agency's most serious health alert—from estrogen patches containing estradiol. The warning had previously suggested the medication could accelerate preexisting breast cancers. Manufacturers including Sandoz and Noven cited the removal of this warning as a primary driver of the current supply challenges.
The American Society of Health-System Pharmacists (ASHP), which tracks manufacturing-level disruptions, currently lists more than a dozen estradiol products from five manufacturers as being in shortage. Sandoz reported that it cannot fully meet "unprecedented demand" caused by the regulatory changes. Another manufacturer, Viatris, stated it is taking steps to expand long-term production capacity. While patches are constrained, other forms of hormone replacement therapy (HRT), including gels, sprays, and oral pills, remain available.
Patients will notice the impact through potential difficulties filling specific prescriptions at their local pharmacies. According to the United States Pharmacopeia (USP), these are "chronic-use" products, meaning even brief interruptions can force patients to halt therapy or switch to alternative treatments. A shift from patches to oral pills carries a concrete change in health risk, as the USP noted patches are often preferred for having a lower risk of venous blood clots and providing a more steady delivery of medication compared to daily pills.
The situation highlights long-term vulnerabilities in the pharmaceutical supply chain, specifically for estradiol. The USP Medicine Supply Map identified that all key starting materials for these products are produced exclusively in China, creating a concentrated risk for U.S. patients. Federal health officials at HHS stated they are monitoring the situation and will update the official shortage list if products become unavailable nationally. For now, manufacturers say they are producing at full capacity, but a timeline for when all manufacturing-level shortages will be resolved remains not reported.